Skip to main content

Table 1 Outcomes which were assessed

From: Efficacy and safety of adding rivaroxaban to the anti-platelet regimen in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials

Trials Outcomes reported Follow-up periods Drugs which were used Dosage of rivaroxaban
ATLAS-ACS 2 TIMI 51 [11] Cardiac death + stroke + MI (composite endpoint), cardiac death, MI, stroke, all-cause death, ST, TIMI minor and major bleeding, Intracranial hemorrhage, fatal bleeding 13 to 31 months Rivaroxaban + DAPT versus DAPT (aspirin + clopidogrel) 2.5 mg or 5 mg twice daily
GEMINI-ACS-1 [12] Cardiac death + stroke + MI + ST (composite endpoint), cardiac death, MI, stroke, all-cause death, ST (definite + probable), TIMI minor and major bleeding, fatal bleeding, intracranial hemorrhage, ISTH major bleeding 1 year Ribaroxaban + clopidogrel/ticagrelor versus aspirin + clopidogrel/ticagrelor 2.5 mg twice daily
COMPASS [13] Cardiac death + stroke + MI (composite endpoint), all-cause death, cardiac death, stroke, MI, fatal bleeding, intracranial hemorrhage, major bleeding according to ISTH criteria 23 months Rivaroxaban + aspirin versus aspirin alone 2.5 mg or 5 mg twice daily
ATLAS-ACS-TIMI 46 [14] TIMI minor and major bleeding, death + MI + stroke (composite endpoint) 6 months Rivaroxaban + DAPT or aspirin versus DAPT (aspirin + clopidogrel) 5 to 20 mg once daily or the same total dose given twice daily
  1. MI myocardial infarction, ST stent thrombosis, TIMI thrombolysis in myocardial infarction, ISTH International Society on Thrombosis and Hemostasis, DAPT dual anti-platelet therapy